GIGA-CARBON-NEUTRALITY
11.11.2021 09:54:11 CET | Business Wire | Press release
Giga Carbon Neutrality (GCN), the clean trucking and technology company, today unveiled a comprehensive range of zero-emission commercial vehicles that it plans to bring to market over the next two years – answering the call from the world’s transportation and logistics operators for a fleet of different options.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005555/en/
GCN will launch 21 different battery-electric and hydrogen fuel-cell powered vehicles by the end of 2023. GCN’s portfolio is configurable to a wide range of commercial use cases and includes a tractor unit, buses and last-mile logistics vehicles. The company’s first prototype hydrogen-fueled tractor unit is currently undergoing advanced road and usability trials in China.
GCN designs its vehicles at a state-of-the-art research and development centre located in Hangzhou , China. GCN has developed its own proprietary hydrogen fuel-cell technology and will source batteries from leading manufacturers initially.
The GCN vehicles are manufactured using lightweight stainless steel and composite materials to improve safety and deliver reductions in weight and energy consumption of at least 10 per cent. The bodies of GCN vehicles are designed to last for 20 years, significantly longer than vehicles from other providers on the market.
GCN is working with public and private sector partners to provide clean energy storage, charging and refueling infrastructure, as well as specialist financing to support the adoption of its zero-emission commercial vehicles globally.
Marty Wade, CEO at Giga Carbon Neutrality, comments: “We are thrilled to give the world its first look at the future of zero-emission commercial transportation.”
“GCN is enabling a carbon-neutral future for some of the world’s most energy-intensive industries, with clean energy vehicles, new technologies and a fueling ecosystem to make running clean, reliable vehicle fleets easy for commercial transportation companies.”
Giga’s initial fleet of zero-emission commercial vehicles
Several GCN vehicles are available to order immediately, with delivery times of between three and 12 months. The company’s initial range includes:
- The GCN Hydrogen Tractor: A 44-tonne hydrogen fuel-cell truck with a top speed of 90 kph and 580 km range before refueling. Streamlined to minimise wind-resistance, GCN’s ‘heavy truck’ features an ergonomic cab design and a range of intelligent safety systems such as driver fatigue warning systems as standard. A prototype of this vehicle is already on the road in China.
- The GCN City Bus: A 12-metre transit bus for urban public transport. Capable of carrying up to 95 passengers, GCN’s city bus has a 350 km range on a battery-electric power train and features a monocoque body and collision protection structure offering improved safety for the driver and passengers. This vehicle is designed to meet European Union approved standards for use in its 27 member states.
- The GCN Pure Electric Minibus: A 6.9-metre battery-electric minibus with an ultra-long wheelbase and flat floor structure to provide capacity for up to 13 passengers. GCN’s minibuses have a 240 km range on a single charge and are already being used on the road in Hong Kong. Autonomous vehicles can also be developed based on this platform.
- The GCN Electric Logistics Vehicle: An 8-tonne battery-electric truck to support last-mile logistics in urban and rural areas. GCN’s logistics truck has a spacious loading area, can be configured to customer needs and can cover 250 km on a single charge.
About Giga Carbon Neutrality (www.gigacarbonneutrality.com )
Giga Carbon Neutrality is a clean energy trucking and technology company with a supporting ‘Energy-as-a-Service’ (EaaS) offering that makes running clean, reliable vehicle fleets easy for industrial and commercial transportation companies. GCN'S portfolio includes battery-electric and hydrogen fuel cell vehicles, clean energy storage, charging and refueling infrastructure, and specialist financing to support the transition to zero-emission vehicles.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
